Impact of vaccination on the presence and severity of symptoms in hospitalized patients with an infection of the Omicron variant (B.1.1.529) of the SARS-CoV-2 (subvariant BA.1).
Impact of vaccination on the presence and severity of symptoms in hospitalized patients with an infection of the Omicron variant (B.1.1.529) of the SARS-CoV-2 (subvariant BA.1).
复制标题
DOI：
10.1016/j.cmi.2022.12.020
复制
发表时间：
2023-05
影响因子：
14.2
通讯作者：
Epaulard, Olivier
中科院分区：
文献类型：
--
作者：
Beraud, Guillaume;Bouetard, Laura;Civljak, Rok;Michon, Jocelyn;Tulek, Necla;Lejeune, Sophie;Millot, Romain;Garchet-Beaudron, Aurelie;Lefebvre, Maeva;Velikov, Petar;Festou, Benjamin;Abgrall, Sophie;Lizatovic, Ivan K.;Boldolli, Aurelie;Esmer, Huseyin;Blanchi, Sophie;Froidevaux, Gabrielle;Kapincheva, Nikol;Faucher, Jean-Francois;Duvnjak, Mario;Afsar, Elcin;Svitek, Luka;Yarimoglu, Saliha;Yarimoglu, Rafet;Janssen, Cecile;Epaulard, Olivier
SARS-CoV-2变种的出现引发了人们对2020年设计的疫苗在多大程度上仍然有效的质疑。我们的目的是评估是否疫苗状态与Omicron SARS-CoV-2感染的严重程度在住院患者。我们在14个中心（保加利亚、克罗地亚、法国和土耳其）进行了一项国际、多中心、回顾性研究。我们收集了2021年12月1日至2022年3月3日期间因PCR证实的感染而住院≥24小时的患者的数据，这些患者在Omicron循环时发生了与感染相关或不相关的住院。排除接受单克隆抗体预防的患者。如果患者接受了至少两次mRNA和/或ChAdOx 1-S注射或一次Ad26.CoV2-S疫苗注射，则认为他们完全接种了疫苗。在1215例患者中（中位年龄73.0岁;四分位距57.0-84.0; 51.3%为男性），746例（61.4%）完全接种疫苗。在多变量分析中，接种疫苗与较低的28天死亡率相关（比值比[95%置信区间]（OR [95 CI]）= 0.50 [0.32-0.77]），入住重症监护室（OR [95 CI] = 0.40 [0.26-0.62]）和需氧量（OR [95 CI] = 0.34 [0.25-0.46]），与年龄和合并症无关。当我们对这些Omicron感染患者和我们最近进行的一项研究中的948例Delta感染患者进行共同分析时，Omicron感染与较低的28天死亡率相关（OR [95 CI] = 0.53 [0.37-0.76]），入住重症监护室（OR [95 CI] = 0.19 [0.12-0.28]）和需氧量（OR [95 CI] = 0.50 [0.38-0.67]），与年龄、合并症和疫苗接种状态无关。最初设计的疫苗对Omicron SARS-CoV-2感染的严重程度仍然有效。Omicron与较低的严重形式风险相关，与疫苗接种和患者特征无关。
The emergence of SARS-CoV-2 variants raised questions about the extent to which vaccines designed in 2020 have remained effective. We aimed to assess whether vaccine status was associated with the severity of Omicron SARS-CoV-2 infection in hospitalized patients. We conducted an international, multi-centric, retrospective study in 14 centres (Bulgaria, Croatia, France, and Turkey). We collected data on patients hospitalized for ≥24 hours between 1 December 2021 and 3 March 2022 with PCR-confirmed infection at a time of exclusive Omicron circulation and hospitalization related or not related to the infection. Patients who had received prophylaxis by monoclonal antibodies were excluded. Patients were considered fully vaccinated if they had received at least two injections of either mRNA and/or ChAdOx1-S or one injection of Ad26.CoV2-S vaccines. Among 1215 patients (median age, 73.0 years; interquartile range, 57.0–84.0; 51.3% men), 746 (61.4%) were fully vaccinated. In multivariate analysis, being vaccinated was associated with lower 28-day mortality (Odds Ratio [95% Confidence Interval] (OR [95CI]) = 0.50 [0.32–0.77]), intensive care unit admission (OR [95CI] = 0.40 [0.26–0.62]), and oxygen requirement (OR [95CI] = 0.34 [0.25–0.46]), independent of age and comorbidities. When co-analysing these patients with Omicron infection with 948 patients with Delta infection from a study we recently conducted, Omicron infection was associated with lower 28-day mortality (OR [95CI] = 0.53 [0.37–0.76]), intensive care unit admission (OR [95CI] = 0.19 [0.12–0.28]), and oxygen requirements (OR [95CI] = 0.50 [0.38–0.67]), independent of age, comorbidities, and vaccination status. Originally designed vaccines have remained effective on the severity of Omicron SARS-CoV-2 infection. Omicron is associated with a lower risk of severe forms, independent of vaccination and patient characteristics.
登录
查看更多内容
影响因子：
15.1
作者：
通讯作者：
--
影响因子：
14.2
作者：
Epaulard, Olivier;Abgrall, Sophie;Lefebvre, Maeva;Faucher, Jean-Francois;Michon, Jocelyn;Frentiu, Emilia;Blanchi, Sophie;Janssen, Cecile;Charbonnier, Gabrielle;Fresse, Audrey;Laurent, Simon;Sandjakian, Lena;Casez, Pierre;Mahamat, Aba;Beraud, Guillaume
通讯作者：
Beraud, Guillaume
DOI：
10.1016/s0140-6736(22)00462-7
发表时间：
2022-04-02
期刊：
Lancet (London, England)
影响因子：
--
作者：
Nyberg T;Ferguson NM;Nash SG;Webster HH;Flaxman S;Andrews N;Hinsley W;Bernal JL;Kall M;Bhatt S;Blomquist P;Zaidi A;Volz E;Aziz NA;Harman K;Funk S;Abbott S;COVID-19 Genomics UK (COG-UK) consortium;Hope R;Charlett A;Chand M;Ghani AC;Seaman SR;Dabrera G;De Angelis D;Presanis AM;Thelwall S
通讯作者：
Thelwall S
影响因子：
64.5
作者：
Cui Z;Liu P;Wang N;Wang L;Fan K;Zhu Q;Wang K;Chen R;Feng R;Jia Z;Yang M;Xu G;Zhu B;Fu W;Chu T;Feng L;Wang Y;Pei X;Yang P;Xie XS;Cao L;Cao Y;Wang X
通讯作者：
Wang X
影响因子：
7.8
作者：
Cheng, Cho-Chin;Platen, Louise;Christa, Catharina;Tellenbach, Myriam;Kappler, Verena;Bester, Romina;Liao, Bo-Hung;Holzmann-Littig, Christopher;Werz, Maia;Schonhals, Emely;Platen, Eva;Eggerer, Peter;Treguer, Laetitia;Kuchle, Claudius;Schmaderer, Christoph;Heemann, Uwe;Renders, Lutz;Protzer, Ulrike;Braunisch, Matthias Christoph
通讯作者：
Braunisch, Matthias Christoph